Adverse events reported in at least 15% of patients in the treated population (N = 66) plus all other events reported at grade 3 or 4 severity
| Event . | Total, n (%) . | Grade 3, n (%) . | Grade 4, n (%) . |
|---|---|---|---|
| Neuropathy, sensory | 53 (80)† | 1 (2) | 0 |
| Fatigue | 42 (64) | 2 (3) | 0 |
| Constipation | 40 (61) | 0 | 0 |
| Edema limb | 30 (45) | 0 | 0 |
| Muscle pain | 29 (44) | 1 (2) | 0 |
| Rash/desquamation | 24 (36) | 1 (2) | 0 |
| Diarrhea | 23 (35) | 0 | 0 |
| Nausea | 21 (32) | 0 | 0 |
| Neuropathic pain | 21 (32) | 2 (3) | 0 |
| Extremity, limb pain | 20 (30) | 2 (3) | 0 |
| Insomnia | 20 (30) | 1 (2) | 0 |
| Hyperglycemia | 18 (27) | 1 (2)‡ | 0 |
| Dizziness | 17 (26) | 2 (3) | 0 |
| Constitutional, other | 12 (18) | 0 | 0 |
| Dyspnea | 12 (18) | 0 | 0 |
| Neuropathy, motor | 12 (18) | 1 (2) | 0 |
| Platelets | 12 (18) | 1 (2) | 3 (5) |
| Pruritis/itching | 12 (18) | 0 | 0 |
| Neutrophils | 10 (15) | 5 (8) | 1 (2) |
| Anxiety | 9 (14) | 1 (2) | 0 |
| Dry skin | 9 (14) | 1 (2) | 0 |
| Lymphopenia | 9(14) | 7 (11) | 2 (3) |
| Vision, blurred | 9 (14) | 1 (2) | 0 |
| Alanine transaminase | 8 (12) | 2 (3)‡ | 0 |
| Hypokalemia | 7 (11) | 3 (5) | 0 |
| Mental status | 7 (11) | 1 (2) | 0 |
| Hyperkalemia | 6 (9) | 1 (2) | 0 |
| Hyponatremia | 6 (9) | 1 (2) | 0 |
| Hypophosphatemia | 6 (9) | 3 (5) | 0 |
| Pulmonary/upper respiratory, other | 6 (9) | 2 (3) | 0 |
| Agitation | 4 (6) | 1 (2) | 0 |
| Hearing | 4 (6) | 1 (2) | 0 |
| Hemoglobin | 4 (6) | 1 (2) | 0 |
| QTc interval | 4 (6) | 2 (3) | 0 |
| Thrombosis/thrombus/embolism | 4 (6) | 2 (3) | 1 (2) |
| Creatinine | 2 (3) | 1 (2) | 0 |
| Leukocytes | 2 (3) | 2 (3) | 0 |
| Atrial fibrillation | 1 (2) | 1 (2) | 0 |
| Infection, other | 1 (2) | 1 (2) | 0 |
| Stomach hemorrhage | 1 (2) | 1 (2) | 0 |
| Event . | Total, n (%) . | Grade 3, n (%) . | Grade 4, n (%) . |
|---|---|---|---|
| Neuropathy, sensory | 53 (80)† | 1 (2) | 0 |
| Fatigue | 42 (64) | 2 (3) | 0 |
| Constipation | 40 (61) | 0 | 0 |
| Edema limb | 30 (45) | 0 | 0 |
| Muscle pain | 29 (44) | 1 (2) | 0 |
| Rash/desquamation | 24 (36) | 1 (2) | 0 |
| Diarrhea | 23 (35) | 0 | 0 |
| Nausea | 21 (32) | 0 | 0 |
| Neuropathic pain | 21 (32) | 2 (3) | 0 |
| Extremity, limb pain | 20 (30) | 2 (3) | 0 |
| Insomnia | 20 (30) | 1 (2) | 0 |
| Hyperglycemia | 18 (27) | 1 (2)‡ | 0 |
| Dizziness | 17 (26) | 2 (3) | 0 |
| Constitutional, other | 12 (18) | 0 | 0 |
| Dyspnea | 12 (18) | 0 | 0 |
| Neuropathy, motor | 12 (18) | 1 (2) | 0 |
| Platelets | 12 (18) | 1 (2) | 3 (5) |
| Pruritis/itching | 12 (18) | 0 | 0 |
| Neutrophils | 10 (15) | 5 (8) | 1 (2) |
| Anxiety | 9 (14) | 1 (2) | 0 |
| Dry skin | 9 (14) | 1 (2) | 0 |
| Lymphopenia | 9(14) | 7 (11) | 2 (3) |
| Vision, blurred | 9 (14) | 1 (2) | 0 |
| Alanine transaminase | 8 (12) | 2 (3)‡ | 0 |
| Hypokalemia | 7 (11) | 3 (5) | 0 |
| Mental status | 7 (11) | 1 (2) | 0 |
| Hyperkalemia | 6 (9) | 1 (2) | 0 |
| Hyponatremia | 6 (9) | 1 (2) | 0 |
| Hypophosphatemia | 6 (9) | 3 (5) | 0 |
| Pulmonary/upper respiratory, other | 6 (9) | 2 (3) | 0 |
| Agitation | 4 (6) | 1 (2) | 0 |
| Hearing | 4 (6) | 1 (2) | 0 |
| Hemoglobin | 4 (6) | 1 (2) | 0 |
| QTc interval | 4 (6) | 2 (3) | 0 |
| Thrombosis/thrombus/embolism | 4 (6) | 2 (3) | 1 (2) |
| Creatinine | 2 (3) | 1 (2) | 0 |
| Leukocytes | 2 (3) | 2 (3) | 0 |
| Atrial fibrillation | 1 (2) | 1 (2) | 0 |
| Infection, other | 1 (2) | 1 (2) | 0 |
| Stomach hemorrhage | 1 (2) | 1 (2) | 0 |